Expression of plasma prekallikrein mRNA in human nonhepatic tissues and cell lineages suggests special local functions of the enzyme by Hermann, Andrea et al.
Biol. Chem., Vol. 380, pp. 1097–1102, September 1999 · Copyright © by Walter de Gruyter · Berlin · New York
Expression of Plasma Prekallikrein mRNA in Human
Nonhepatic Tissues and Cell Lineages Suggests Special
Local Functions of the Enzyme
Andrea Hermanna, Marianne Arnhold,
Hans Kresse, Peter Neth and Edwin Fink*
Abteilung für Klinische Chemie und Klinische Biochemie
in der Chirurgischen Klinik und Poliklinik,
Klinikum Innenstadt, Ludwig-Maximilians-Universität,
Nußbaumstr. 20, D-80336 München, Germany
* Corresponding author
At present it is generally accepted that plasma
prekallikrein (PPK) is synthesized in the liver and se-
creted into the bloodstream. Surprisingly, it has re-
cently been shown that PPK mRNA is present also in
RNA from the kidney, adrenal gland and placenta. In
spite of its novelty and possible important physiologi-
cal implications this finding has been neglected. Here
we report that PPK mRNA is expressed also in the hu-
man brain, heart, lung, trachea, endothelial cells and
leukocytes as well as in a variety of fibroblast and ep-
ithelial cell lines. Expression of PPK mRNA in fibrob-
lasts, endothelial cells and leukocytes suggests that
PPK mRNA detected in RNA preparations from whole
tissue may originate solely from these ubiquitously oc-
curring cells. However, PPK mRNA expression in vari-
ous epithelial cell lines demonstrates that tissue-spe-
cific cells also transcribe the PPK gene. The presence
of PPK mRNA in nonhepatic tissues and cells indi-
cates that they have the capacity to synthesize the
protein. The physiological role of PPK synthesized in
extrahepatic tissue is unknown. It may participate in
local actions within tissues as well as contributing to
the PPK pool in blood plasma. Cultured cells will pro-
vide a valuable model for exploring the physiological
significance of extrahepatic PPK expression.
Key words: Contact activation / Kallikrein-kinin system /
Plasma kallikrein / Reverse transcription PCR / RT-PCR.
Introduction
Plasma prekallikrein (PPK), the zymogen of the serine pro-
teinase plasma kallikrein (PK; EC 3.4.21.34) is synthesized
in hepatocytes and secreted into the blood stream (Bhoola
et al., 1992). Its concentration in plasma is about 50 mg/l of
which seventy five percent is complexed with high molec-
ular weight kininogen (HK). The active enzyme is generat-
ed in the contact system, the early phase of the intrinsic
pathway of blood coagulation. The contact system is acti-
vated when plasma is exposed to negatively charged sur-
faces: the PPK-HK complex is bound via cationic regions
of domain 5 of HK to the anionic surface (Mandle et al.,
1976), and activated factor XII (FXIIa) generates plasma
kallikrein which in turn produces FXIIa (Mandle and Ka-
plan, 1977). Thus, by a positive feedback reaction, a local
increase in the concentration of both PK and FXIIa is
achieved.
The two proteinases, PK and FXIIa, generated during
contact activation can be involved in a number of sub-
sequent processes. Both enzymes can activate granulo-
cytes (Schapira et al., 1982, 1983; van der Graaf et al.,
1982; Wachtfogel et al., 1983, 1986) and the complement
system (Ghebrehiwet et al., 1981, 1983; DiScipio, 1982).
FXIIa activates factor XI and in this manner triggers the in-
trinsic blood coagulation cascade. PK is an efficient acti-
vator of urokinase-type plasminogen activator precursor
and thus provides a link to the fibrinolysis system (Ichinose
et al., 1986; Hauert et al., 1989). Probably the second most
important function of PK, next to its participation in the
contact activation system, is its action as a kinin-liberating
enzyme in the kallikrein-kinin system (Bhoola et al., 1992).
Recently, Ciechanowicz et al. (1993) and our group
(Hermann et al., 1996) found by reverse transcription PCR
that PPK mRNA is present in RNA preparations from
whole tissues of kidney, adrenal gland and placenta. Thus,
in contrast to the generally accepted concept that plasma
kallikrein is synthesized solely in the liver, one has to con-
clude that synthesis of PPK also takes place outside the
liver and that the enzyme may have special, hitherto un-
known local function(s). The surprising new finding of ex-
trahepatic PPK mRNA synthesis and its potential impor-
tance with respect to functions of PPK/PK have obviously
been overlooked, since no subsequent work on these top-
ics has been reported.
The previous results (Ciechanowicz et al., 1993; Her-
mann et al., 1996) did not indicate whether PPK mRNA is
expressed by ubiquitous cells like fibroblasts, endothelial
cells, and white blood cells, or by tissue-specific cells.
Therefore, in order to clarify this issue and to find a model
system for investigating the physiological significance of
extrahepatic PPK synthesis, we undertook a study on PPK
mRNA expression in cultured human fibroblasts and
epithelial cells originating from different human tissues.
Additionally, a variety of human tissues was examined for
expression of PPK mRNA.
a Present address: november AG, Ulrich-Schalk-Str. 3a,
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Results
Expression of PPK mRNA in Human Cell Lines
and Tissues
In order to examine whether tissues other than those re-
ported as well as cultured cells express mRNA of plasma
prekallikrein, a semi-nested RT-PCR was performed with
total RNA of a variety of human tissues and cell lines. To
confirm the identity of the amplicons, restriction frag-
ments were prepared by incubating aliquots of the PCR
mixtures with the endonuclease SacI. The sizes of the
PCR products and restriction fragments were determined
by polyacrylamide gel electrophoresis. The silver stained
gel of a typical experiment representing the result for RNA
from HeLa cells is shown in Figure 1. For comparison sam-
ples of a PCR with leukocyte genomic DNA before and af-
ter digestion with SacI (lanes 4 and 5) were also applied
onto the gel. Figure 1 demonstrates that with RT-PCR of
mRNA of HeLa cells a product of the size predicted for
plasma prekallikrein mRNA (394 bp, R in lane 1; cf. Fig-
ure 2) is obtained, and that by digestion with SacI frag-
ments of the expected lengths are produced (312 bp + 4 b
and 78 bp + 4 b, R-F1 and R-F2 in lane 2; the cleavage site
of SacI in the upper strand of the cDNA is located between
bases 1195 and 1196, Figure 2). Figure1 indicates that 
the RNA preparation was not absolutely free of genomic
DNA since, in addition to the amplicon of the cDNA, a PCR
product (G in lane 1,  900 bp) and SacI digestion frag-
ments (G-F1,  663 bp + 4b, and G-F2, 233 bp + 4b, in lane
2) of the sizes expected for genomic DNA (lanes 4 and 5)
were obtained. 
Further proof that the amplicons R and G resulted in-
deed from mRNA and genomic DNA of PPK was gained by
DNA sequence analysis of the PCR-products of HeLa
cells using the forward primer hPK-29F. Except for some
ambiguities, the readable sequences (Figure 2) were iden-
tical to the known sequences of PPK cDNA (880–1273 of
GenBank accession number M13143) and intron 8 (Kuna-
puli et al., 1995). The amplicon G must contain the three in-
trons 8, 9 and 10 inserted after the positions 961, 1124 and
1237 of the cDNA sequence (Asakai et al., 1987; Beaubien
et al., 1991; Kunapuli et al., 1995); the sequences of intron
8 and 10 have been elucidated previously (Kunapuli et al.,
1995). The full-length intron 8 was found at the reported
site (Figure 2). The exon-9/intron-9 junction is expected
at position 367–368 of amplicon G where, in fact, the se-
quence started to differ from the known cDNA sequence
(Figure 2). As calculated from the sizes of amplicon G
(about 900 bp, cf. Figure 1), of introns 8 and 10 (158 and
Fig.1 Expression of Plasma Prekallikrein mRNA in HeLa Cells
Demonstrated by Semi-Nested RT-PCR.
Total RNA was extracted from cultured HeLa cells and reverse
transcribed using a specific primer for PPK. Semi-nested PCR
was performed with the cDNA and genomic DNA. Aliquots of
these reaction mixtures with and without SacI digestion were
subjected to PAGE. DNA bands were visualized by silver staining.
Lane 1: cDNA; lane 2: cDNA after SacI digestion; lane 3: DNA size
standard; lane 4: genomic DNA after SacI digestion; lane 5: ge-
nomic DNA; lane 6: negative control (semi-nested PCR was per-
formed with a sample where in the reverse transcription step the
RNA solution had been replaced by water). Designations of
bands: G, G-F1, G-F2: amplicon of genomic DNA and its SacI di-
gestion fragments; R, R-F1, R-F2: amplicon of cDNA and its SacI
digestion products (for details see Figure 2 and Results).
Table1 Expression of Plasma Prekallikrein mRNA in Fibroblast
and Epithelial Cell Lines Derived from Various Human Tissues.
Cell line or tissue Comments PPK mRNA
WI 38 Fibroblasts (lung) +
Colo 668 Fibroblasts (colon) +
Decidua Fibroblasts +
(primary culture)
HaCaT Keratinocytes +
HaCaT II-4RT Keratinocytes +
PancTu Pancreatic tumor +
(epithelial)
BT 20 Mammary tumor +
(epithelial)
SW 480 Colon carcinoma +
(epithelial)
HT 29 Colon carcinoma +
(epithelial)
Kato III Stomach carcinoma +
(epithelial)
HeLa Cervix carcinoma +
(epithelial)
HUVEC Primary culture +
Neutrophils Freshly isolated +
Brain Whole tissue +
Heart Whole tissue +
Lung Whole tissue +
Trachea Whole tissue +
Liver Whole tissue +
Kidney Whole tissue +
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155 bp, Kunapuli et al., 1995) and of the cDNA segment
(394 bp), intron 9 has a length of about 200 bp. Intron 10 is
not contained in the sequenced section of amplicon G. 
The same electrophoresis results as for HeLa cells,
demonstrating the expression of plasma prekallikrein
mRNA were obtained for total RNA from all cell lines inves-
tigated (Table 1) and from human liver, kidney, brain, heart,
lung, trachea, HUVECs (human umbilical vein endothelial
cells) and leukocytes.
Discussion
Specificity of RT-PCR
The primers for reverse transcription and PCR were se-
lected in such a manner that amplicons of genomic DNA
contained three introns and, therefore, were easily distin-
guishable from the 394 bp PCR product of cDNA by elec-
trophoretic size determination. Indeed, when PCR was
performed with genomic DNA a single product of about
900 bp was obtained (Figure 1, lane 5), demonstrating that
the amplicon of genomic DNA cannot be confused with
that of cDNA and, in addition, that the human genome
does not contain retropseudogenes of PPK that could give
rise to PCR products of similar size as that of PPK cDNA.
Further confirmation that the amplicon resulted from
mRNA was achieved by digestion with SacI which pro-
duced fragments of the correct lengths of 312 bp and 78
bp (Figure 1, lane 2). Like the undigested PCR products,
these fragments were unequivocally distinguishable from
those resulting from genomic DNA with predicted chain
lengths of  663 bp and 233 bp (lanes 2 and 4). In addition,
in the case of HeLa cells the identity of the cDNA amplicon
was verified by sequence determination (Figure 2).
Partial DNA sequence determination of the  900 bp
PCR product revealed that it indeed represented the am-
plicon of the respective PPK gene segment (Figure 2). The
sequence was as expected for cDNA but with intron se-
quences inserted in the positions reported by Kunapuli
et al. (1995), and as deduced from the homology of PPK
with human factor XI (Asakai et al., 1987) and rat PPK
(Beaubien et al., 1991). The  900 bp band was observed
in several RT-PCR experiments indicating some contami-
nation of the RNA preparations with genomic DNA (cf.
Figure1, lane 1). However, since both the RT-PCR product
of PPK mRNA and its restriction fragments are unequivo-
cally distinguishable from those of genomic DNA, no ef-
forts were undertaken to achieve complete removal of ge-
nomic DNA from the RNA preparations. Taken together,
the method of semi-nested RT-PCR combined with chain
length estimation by PAGE and restriction fragment analy-
sis provides a sensitive and specific means for the detec-
tion of PPK mRNA. It guarantees unambiguous results
even in the presence of genomic DNA; further confirma-
tion by DNA sequence analysis is not required.
Expression of PPK mRNA in Nonhepatic
Tissues and Cell Lines
Plasma kallikrein is a serine proteinase that is present in
blood as the inactive zymogen plasma prekallikrein. It is
generally accepted that PPK is synthesized in hepato-
cytes and secreted into the blood where it circulates main-
ly as a heterodimer complex with high molecular weight
kininogen, and is available for participating in multiple
Extrahepatic Expression of Plasma Prekallikrein mRNA 1099
Fig.2 Comparison of the Sequences Determined for Amplicons G and R with Known Sequence Data.
The sequences determined for amplicons G and R (lines with prefixes G and R, respectively) are aligned to the segment 880–1273 of the
cDNA sequence of human plasma kallikrein (GenBank accession number M13143) with the intron 8 (Kunapuli et al., 1995) inserted. Intron
sequences are in lower case letters. The primer hPK-29F used for sequencing corresponds to bases 880–898. The cleavage site for SacI
is between bases 1195 and 1196. Symbols for not clearly identified nucleotides: P: A/G; Q: C/T; R: A/ T; W: G/T; N: A/C/G/T.
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physiological processes (see Introduction). Its synthesis in
the liver was originally deduced from the fact that circulat-
ing levels of PPK were reduced in patients with liver cir-
rhoses (Colman and Wong, 1979). Direct evidence of
hepatic PPK synthesis came from immunocytochemical
studies using confocal laser scanning microscopy which
demonstrated PPK in hepatocytes (Henderson et al.,
1992). Recently, Ciechanowicz et al. (1993) and our group
(Hermann et al., 1996) provided evidence for extrahepatic
synthesis of PPK: by employing RT-PCR, expression of
PPK mRNA was detected in human liver, kidney, adrenal
gland and placenta. The aim of the present study was to
clarify whether PPK mRNA is expressed in tissues other
than the liver and in tissue-specific cells, and to find a
model for studying extrahepatic PPK synthesis and its
regulation. We therefore analyzed RNA from various tis-
sues, from leukocytes, from primary culture of human um-
bilical vein endothelial cells and from cell lines of fibrob-
lasts and epithelial cells. We found that PPK mRNA is pre-
sent in all of them (Table 1). The presence of PPK mRNA in
the ubiquitously occurring fibroblasts, leukocytes and en-
dothelial cells may suggest that these cell types are the
only ones expressing PPK mRNA extrahepatically. How-
ever, the PPK gene is transcribed also in epithelial cell lines
originating from different organs (Table 1). Thus, the re-
sults indicate that expression of PPK mRNA and assum-
ingly also of the protein takes place not only in ubiquitous
cells but also in tissue-specific epithelial cells throughout
the organism. The final answer to the question as to which
of the cells in the various tissues express PPK mRNA will
be arrived at from in situ hybridization or in situ RT-PCR
studies.
Extrahepatic Synthesis of PPK
Expression of a mRNA provides strong indication, but
does not necessarily prove synthesis of the respective
protein. Synthesis of PPK has until now been shown only
in the liver by Henderson et al. (1992) who demonstrated
immunoreactive PPK in isolated human hepatocytes by
confocal laser scanning microscopy and in sections of liv-
er by light microscopy. Seidah et al. (1988) isolated plasma
kallikrein from human pituitary gland, however, they could
not exclude the possibility that the enzyme resulted from
blood or the extravascular bed. Even though no unam-
biguous evidence of extrahepatic synthesis of PPK has
been presented, the transcription of the gene in various
tissues and cell lines demonstrates that extrahepatic syn-
thesis of PPK is possible, but final proof will have to come
from studies at the protein level.
Possible Physiological Functions of
Extrahepatically Synthesized PPK
The physiological function of PPK synthesized in extra-
hepatic tissues can only be speculated upon. It may con-
tribute to the PPK pool in blood plasma or cause local
activation of various proenzymes (cf. Introduction). Also,
concluding from in vitro studies, local processing of pro-
hormones seems possible (Seidah et al., 1988). We favor
the idea that PPK synthesized in extrahepatic tissues may
function as a local kininogenase, acting similar to glandu-
lar (tissue) kallikrein in an autocrine- or paracrine-like man-
ner. Glandular kallikrein is completely different from PK
(Bhoola et al., 1992); the two enzymes have in common
that they liberate kinin from kininogens, PK releases
bradykinin, glandular kallikrein lysyl-bradykinin. Consis-
tent with this hypothesis are our studies on mRNA expres-
sion of other components of the kallikrein-kinin system
which demonstrate that the genes of high molecular
weight kininogen (manuscript submitted) and FXII (unpub-
lished results) are transcribed also in many nonhepatic
tissues and cells. Thus it appears reasonable to assume
that many tissues are furnished with a complete plasma
kallikrein-kinin system that can become activated and
exert local effects.
Our results confirm the reports of Ciechanowicz et al.
(1993) and Hermann et al. (1996) and demonstrate that the
PPK gene is transcribed in an even larger variety of tissues
and cells than reported by these authors. Inferring from the
results with epithelial cell lines, not only ubiquitously oc-
curring cells are the origin of PPK mRNA but also tissue-
specific cells. The next steps will be to verify extrahepatic
PPK protein synthesis by immunocytochemical methods
and to perform studies on cell lines with respect to PPK
synthesis and its regulation.
Materials and Methods
Cell Lines and Cell Culture Conditions
Human keratinocyte cell lines HaCaT, a spontaneously immor-
talized aneuploid cell line (Boukamp et al., 1988) and HaCaT II-
4RT, derived from HaCaT by transfection with the c-Ha-ras (EJ)
oncogene (Boukamp et al., 1990) were kind gifts of Dr. N. E.
Fusenig (German Cancer Research Center, Heidelberg). PancTu
cells (Kalthoff et al., 1993) were kindly provided by Dr. K. Pantel
(Institute of Immunology, University of Munich), primary cultures
of decidua cells by Dr. J. Rehbock (Hospital of Gynecology, Uni-
versity of Munich) and primary cultures of human umbilical vein
endothelial cells (HUVEC) and leukocytes by Dr. I. Müller (our in-
stitute). WI 38, SW 480, Kato III, BT 20 and HT 29 were from Amer-
ican Type Culture Collection, Colo 668 cells from the German
Collection of Microorganisms and Cell Culture (Braunschweig,
Germany), HeLa cells from EACC, Salisbury, UK.
Cells were cultured at 37°C in a humidified atmosphere of 5%
CO2 and 95% air. HaCaT, HaCaT II and WI 38 were grown in
DMEM medium containing 1 g/l glucose (PAA, Cölbe, Germany),
supplemented with 0.35g/l L-glutamine, 0.05g/l gentamicin
sulfate (Biowhittaker, Boehringer Ingelheim, Germany) and 10%
fetal calf serum (PAA, Cölbe, Germany). Colo 668, decidua, BT 20,
HT 29, SW 480 and PancTu cells were grown in RPMI medium
(Biowhittacker), supplemented with 0.35g/l L-glutamine, 100 U/
ml penicillin, 0.1 g/l streptomycin (Sigma, Deisenhofen, Germany)
and 10% fetal calf serum (PAA).
After reaching confluence cells were harvested by incubation
with 0.5 g/l trypsin and 0.2 g/l EDTA (Sigma) for 10 min. The prote-
olytic activity of trypsin was stopped by the addition of medium
containing fetal calf serum. The cells were isolated from the sus-
pensions (centrifugation at 200 g for 10 min) and washed twice
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with phosphate buffered saline. Aliquots of about 107 cells were
stored at –70°C in RNase-free plastic tubes until use.
RNA Preparation
Total RNA was extracted from cultured cells and leukocytes by
using the method described by Chomzynski and Sacchi (1987).
Briefly, about 107 cells were lysed with 500 l nucleic acid extrac-
tion buffer (4 M guanidine isothiocyanate, 5 g/l N-laurylsarcosine
sodium salt, 0.1 M 2-mercaptoethanol, 25mM sodium citrate, pH
7). 50l of 2 M sodium acetate pH 5.2 were added to the ho-
mogenates. The suspension was extracted with 500l phenol
and 100l of a chloroform/isoamyl alcohol mixture (49:1, v/v) and
centrifuged at 13000 g. The RNA dissolved in the aqueous phase
was precipitated with ethanol and suspended in diethyl-
pyrocarbonate-treated water. The isolated RNA was quantified
spectrophotometrically at 260 nm. A negative control was ob-
tained by performing the whole procedure without adding cells.
Total RNA from human liver, kidney, brain, heart, lung, and trachea
was purchased from Clontech Laboratories (Paolo Alto, USA;
catalog number K4000-1).
Reverse Transcription and PCR
Primers for semi-nested RT-PCR were selected from the cDNA
sequence of human PPK (GenBank accession number M13143)
taking into consideration the partially known exon-intron organi-
zation (Kunapuli et al., 1995) that the PCR product included three
exon-exon transitions. All primers were synthesized by MWG-
Biotech (Ebersberg, Germany). The primers used were: hPK-29F,
5-AGTGG CACAC CAAGT TCCT-3 (880–898, in exon 8), hPK-
422R, 5-CTCCA ACAAT GCGTG TGCT-3 (1273–1255, in exon
11), hPK-486R, 5-TGAGC TGTCA GCTTC ACCT-3 (1337–
1319, in exon 11). The quality of mRNA and cDNA preparations
was validated by RT-PCR amplifying a segment of the ribosomal
protein RPS4X (GenBank accession number M58458) using the
forward primer RPX-1, 5-TTCCT TGCCT AACGC AGC-3, and
the reverse primer RPX-2, 5-GATCT CACAT GTCAC CCA-3.
cDNA of plasma prekallikrein and RPS4X was synthesized us-
ing a First Strand cDNA Synthesis Kit (Pharmacia, Freiburg, Ger-
many). 1g of total RNA or a corresponding volume of the nega-
tive control was incubated with 1l of 200mM dithiothreitol, 50 ng
of the outer reverse primer hPK-486R, 50 ng of primer RPX-2 and
RNase-free water in a final volume of 10l. The incubation was
performed at 65°C for 10 min and then the mixture was placed
on ice. 5l of the ‘Bulk First Strand Reaction Mix’ (Pharmacia,
Freiburg, Germany), containing murine reverse transcriptase,
RNAguard, bovine serum albumin and deoxynucleotide triphos-
phates, were added and the mixture incubated at 37°C for 2 h.
The first PCR was performed with 1l of cDNA synthesis reac-
tion mixtures, of the negative control, and of genomic DNA. To
these samples 5l of Taq DNA polymerase buffer (100mM Tris-
HCl pH 9.0, 500mM KCl, 15mM MgCl2, 1 g/l gelatin, 1% Triton X-
100), 1l of 20mM dNTP solution (Pharmacia, Freiburg, Ger-
many), 50 ng of the outer reverse primer (hPK-486 R) and 50 ng of
the forward primer (hPK-29F), autoclaved water up to 50l and
0.5 units of Taq DNA polymerase (Boehringer Mannheim, Ger-
many) were added. 20 cycles of PCR amplification were per-
formed each one consisting of a denaturation step at 92°C for
30 s, an annealing step at 52°C for 30 s and an elongation step at
72°C for 30 s.
The second PCR with the forward primer hPK-29F and the in-
ner reverse primer hPK-422R was performed with 1l of the 1:10
diluted reaction mixture of the first PCR. 35 cycles were run with
the profile described above. PCR for RPS4X cDNA amplification
was performed only in the second PCR using the primers RPX-1
and RPX-2.
Restriction Analysis
Aliquots of 4l of the PCR mixtures of cDNA and genomic DNA
were incubated at 37°C for 2 h with 7.5 U of the restriction enzyme
SacI (Boehringer Mannheim, Germany) and 0.4l cleavage
buffer. A third aliquot remained undigested and was diluted to the
same volume.
Size Determination by PAGE
For size determination the PCR products, restriction fragments
and a DNA size marker (G1751, Promega, Mannheim, Germany)
were subjected to PAGE on a 14.5% acrylamide gel in 44.5mM
Tris, 44.5mM boric acid, 1.0mM EDTA, pH 8.0. DNA bands were
visualized by silver staining (Riesner et al., 1989).
Sequence Analysis
PCR products were purified by agarose gel electrophoresis and
subsequent isolation of the respective band from the gel using
a QIAquick gel extraction kit (Qiagen, Hilden, Germany). Nu-
cleotide sequences were analyzed by the dideoxynucleotide
chain-termination method using the Dye Terminator Cycle Se-
quencing Ready Reaction Kit (Perkin-Elmer, Weiterstadt, Ger-
many) and an ABI PRISM 377 DNA sequencer (Perkin-Elmer).
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